Market Cap (In NOK)
53 Million
Revenue (In NOK)
2.99 Million
Net Income (In NOK)
-20.31 Million
Avg. Volume
64.17 Thousand
- Currency
- NOK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.1-3.5
- PE
- -
- EPS
- -
- Beta Value
- 1.727
- ISIN
- NO0010405640
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Ronny Skuggedal
- Employee Count
- -
- Website
- https://www.pcibiotech.com
- Ipo Date
- 2008-06-23
- Details
- PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense. PCI Biotech Holding ASA is based in Oslo, Norway.
More Stocks
-
APLMApollomics, Inc.
APLM
-
IDWM
-
PTXLF
-
603320
-
CIE
-
603393
-
MEGACPO
-
ALVETTheraVet SA
ALVET